Bristol Myers (BMY) said studies demonstrated iza-bren achieved statistically significant in overall survival and progression-free survival in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer
#BRISTOL-MYERS SQUIBB CO#BMY.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#BMY#US EQUITIES